Spikes from AstraZeneca COVID-19 vaccine resemble SARS-CoV-2 S proteins 8 April 2021 | By Victoria Rees (Drug Target Review) Using cryo-electron microscopy, researchers have shown that the Spike (S) protein on cells exposed to the AstraZeneca vaccine is highly similar to the SARS-CoV-2 S protein.
New single-cell transcriptomics method does not put cells under stress 8 April 2021 | By Victoria Rees (Drug Target Review) Researchers have created a new single-cell transcriptomics approach that cryopreserves cells, limiting the stress they are put under.
Researchers discover strategy to reverse poor stress response in mice 8 April 2021 | By Victoria Rees (Drug Target Review) Studying the mouse gene Ophn1, researchers have found its removal causes stressed behaviours, also identifying three ways to reverse this effect.
Dynamic model of SARS-CoV-2 S protein reveals vaccine targets 7 April 2021 | By Victoria Rees (Drug Target Review) A model of the SARS-CoV-2 Spike protein surface has uncovered vulnerabilities that researchers say could inform the development of COVID-19 vaccines.
Team reveals miR-29 as regulator of processes for normal brain maturation 7 April 2021 | By Victoria Rees (Drug Target Review) Researchers have shown that miR-29 can control brain maturation in mammals, presenting a target for autism, epilepsy and other conditions.
Technique developed for delivery of iPSCs to treat type I diabetes mellitus 6 April 2021 | By Victoria Rees (Drug Target Review) A team has developed a lotus-root-shaped construct to deliver iPSC-derived pancreatic beta-cells to patients with type I diabetes mellitus.
X-ray screening reveals two promising SARS-CoV-2 drug candidates 6 April 2021 | By Victoria Rees (Drug Target Review) Using a high-brilliance X-ray lightsource and protein crystallography, researchers have identified two drugs that inhibit the main protease of SARS-CoV-2.
Alliance to create atlas of human genetic variants launched 6 April 2021 | By Victoria Rees (Drug Target Review) The Atlas of Variant Effects Alliance will develop a map of human genetic variants to advance the understanding and treatment of disease.
Novel Zika virus vaccine shows success in pre-clinical trials 6 April 2021 | By Victoria Rees (Drug Target Review) A new VLP-based Zika virus vaccine is able to protect mice completely from infection, researchers have found.
Revealed structure of enzyme could progress cancer research 5 April 2021 | By Victoria Rees (Drug Target Review) Researchers have elucidated the 3D structure of the Taspase 1 enzyme, known to be involved in a range of cancers.
Inhibiting Asc-1 protein function could present new drug target for obesity 5 April 2021 | By Victoria Rees (Drug Target Review) Researchers have shown that loss of Asc-1 function could help obese patients maintain a healthy metabolism.
Gold nanoparticles designed to seek out and isolate human bone stem cells 2 April 2021 | By Victoria Rees (Drug Target Review) A team has designed gold nanoparticles to reveal specific bone stem cells, which could lead to treatments for major bone fractures.
Novel opioid could provide pain relief alternative to fentanyl 2 April 2021 | By Victoria Rees (Drug Target Review) NFEPP, a new opioid, inhibited colon pain in mice with colitis but did not cause the side effects associated with use of fentanyl.
Tumour cell vaccine strategy developed for neuroblastoma and melanoma 1 April 2021 | By Victoria Rees (Drug Target Review) A combination of checkpoint and small molecule inhibitors showed success at targeting Myc oncogenes in mouse neuroblastoma and melanoma models.
New in vitro assay developed to test potential NASH drugs 1 April 2021 | By Victoria Rees (Drug Target Review) An assay that combines 3D disease models and automated AI-based fibrosis quantification could accelerate NASH drug discovery.
